Increasing the Bioavailability of RuIIIAnticancer Complexes through Hydrophobic Albumin Interactions
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increasing the Bioavailability of RuIIIAnticancer Complexes through Hydrophobic Albumin Interactions
Authors
Keywords
-
Journal
CHEMISTRY-A EUROPEAN JOURNAL
Volume 19, Issue 50, Pages 17031-17042
Publisher
Wiley
Online
2013-11-07
DOI
10.1002/chem.201302671
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study
- (2013) Aviva Levina et al. CHEMISTRY-A EUROPEAN JOURNAL
- X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)
- (2013) Alfred A. Hummer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies
- (2012) Orsolya Dömötör et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells
- (2012) Jade B. Aitken et al. Metallomics
- NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
- (2012) Robert Trondl et al. BMC Pharmacology & Toxicology
- Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(iii) complex NAMI-A by interactions with human serum albumin
- (2011) Michael I. Webb et al. DALTON TRANSACTIONS
- Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
- (2011) Alberta Bergamo et al. DALTON TRANSACTIONS
- Pyridine Analogues of the Antimetastatic Ru(III) Complex NAMI-A Targeting Non-Covalent Interactions with Albumin
- (2011) Michael I. Webb et al. INORGANIC CHEMISTRY
- Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors
- (2011) M.M. Henke et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Impact of albumin on drug delivery — New applications on the horizon
- (2011) Bakheet Elsadek et al. JOURNAL OF CONTROLLED RELEASE
- Clinical impact of serum proteins on drug delivery
- (2011) Felix Kratz et al. JOURNAL OF CONTROLLED RELEASE
- Approaching tumour therapy beyond platinum drugs
- (2011) A. Bergamo et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- LC– and CZE–ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(iii)] (KP1339) in mouse plasma
- (2011) Anna K. Bytzek et al. Metallomics
- Targeted Nanogels: A Versatile Platform for Drug Delivery to Tumors
- (2011) E. A. Murphy et al. MOLECULAR CANCER THERAPEUTICS
- Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
- (2010) Petra Heffeter et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Organometallic Anticancer Compounds
- (2010) Gilles Gasser et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study
- (2009) Frederike Lentz et al. ANTI-CANCER DRUGS
- Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR
- (2009) Naniye Cetinbas et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Using Multiconformation Continuum Electrostatics to Compare Chloride Binding Motifs in α-Amylase, Human Serum Albumin, and Omp32
- (2009) Yifan Song et al. JOURNAL OF MOLECULAR BIOLOGY
- Recent developments in ruthenium anticancer drugs
- (2009) Aviva Levina et al. Metallomics
- KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
- (2008) Christian G. Hartinger et al. CHEMISTRY & BIODIVERSITY
- Synthesis and Reactivity of the Aquation Product of the Antitumor Complextrans-[RuIIICl4(indazole)2]−
- (2008) Berta Cebrián-Losantos et al. INORGANIC CHEMISTRY
- The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin
- (2008) Malgorzata Brindell et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Application of capillary electrophoresis–inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins
- (2008) Kasia Połeć-Pawlak et al. JOURNAL OF CHROMATOGRAPHY A
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- CZE–ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP
- (2008) Michael Groessl et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Metal-Ligand Exchange Kinetics in Platinum and Ruthenium Complexes
- (2008) By Jan Reedijk
- Antitumour metal compounds: more than theme and variations
- (2007) Michael A. Jakupec et al. DALTON TRANSACTIONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started